Healthcare Private Placement and M&A Transactions Review Week Ending December 1, 2024

Scan.com: The company raised GBP 59.2 million of venture funding through a combination of debt and equity on November 28, 2024. GBP 38.2 million of Series C was from undisclosed investors. The company is a developer of an accessible diagnostic imaging platform.

Cradle: The company raised $73 million of Series B venture funding in a deal led by IPV Capital on November 26, 2024. IVP, Index Ventures and Kindred Capital also participated in the round. The company is a developer of an algorithm and artificial intelligence tool designed to help teams engineer proteins faster.

35Pharma: The company raised $53 million of Series C venture funding in a deal led by Frazier Healthcare Partners on November 26, 2024. venBio, Vivo Capital, Deep Track Capital, Paradigm BioCapital, Columbia Threadneedle Investments, Surveyor Capital, Marshall Wace, Janus Henderson Investors and Logos Capital also participated in the round. The company is an operator of a biopharmaceutical business intended for pulmonary hypertension and musculoskeletal disorders.

Sirona: The company raised $42 million of Series C venture funding through a combination of equity and debt in a deal led by Avidity Partners on November 26, 2024. 8VC, GreatPoint Ventures and other undisclosed investors also participated in the round. The company is a developer of a radiology operating system.

Tasca Therapeutics: The company raised $24.2 million of venture funding from undisclosed investors on November 26, 2024. The company is an operator of a biotechnology business intended to develop small molecule drugs for hard-to-treat oncology indications.

Secretome Therapeutics: The company raised $20.4 million of venture funding in a deal led by Huffines Enterprises Science & Technology on November 25, 2024. Phillip Huffines also participated in the round. The company is a developer of a cell-based therapy designed for patients who experience a heart attack and advanced heart failure.

Waltz Health: The company raised $17.5 million of venture funding from undisclosed investors on November 27, 2024. The company is a developer of an AI-powered marketplace to optimize prescription drug pricing and distribution.

Doron Therapeutics: The company raised $11 million of Series A venture funding in a deal led by SPRIM Global Investments on November 25, 2024. The company is an operator of a clinical-stage biotech business focusing on degenerative musculoskeletal conditions.

Nia Therapeutics: The company raised $10.4 million of venture funding from Ben Franklin Technology Partners of Southeastern Pennsylvania and Paeonia Group on November 25, 2024, putting the company’s pre-money valuation at $30.5 million. The company is a developer of a neurostimulation device designed to stimulate memory for patients with traumatic brain injury.

PocDoc: The company raised GBP 5 million through a combination of debt and venture funding in a deal led by Simplyhealth, Molten Ventures and MMC Ventures on November 26, 2024, putting the company’s pre-money valuation at GBP 13.4 million. KHP Ventures and other undisclosed investors also participated in the round. The company is a developer of a digital health platform that uses rapid diagnostic testing to get real-time analysis of lifestyle diseases.

PhotoniCare: The company raised $4.6 million of venture funding from undisclosed investors on November 27, 2024. The company is a developer of ear diagnosis devices for middle ear infections.

GuideAI Health: The company raised an undisclosed amount of venture funding from C10 Labs in December 2024. The company is a developer of an AI-powered platform designed to improve early detection and diagnosis of chronic vascular disease.

Poseida Therapeutics / Roche: The company reached a definitive agreement to be acquired by Roche for a total equity value of up to $1.5 billion on November 26, 2024. Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients.

Carragelose / Unither Pharmaceuticals: The company a subsidiary of Translink Corporate Finance, entered into a definitive agreement to be acquired by Unither Pharmaceuticals, via its financial sponsors GIC Private, IK Partners, Keensight Capital, NiXEN Partners, and Parquest Capital through a $20 million LBO on November 26, 2024. The company is an operator of a novel antiviral compound intended to prevent and treat respiratory infections.

ALZET Osmotic Pumps / Lafayette Instrument Company: The company, a subsidiary of Durect, was acquired by Lafayette Instrument Company, via its financial sponsor Branford Castle Partners, through an LBO on November 22, 2024 for $17.5 Million. The company is a manufacturer of infusion pumps and related accessories designed for universities and research institutions.

Orb Health / Respiri: The company reached a definitive agreement to be acquired by Respiri for $9 million on November 26, 2024. The company is a developer of a collaborative care platform designed to offer scalable chronic care management to improve patient outcomes.

Galen Data / Lauxera Capital Partners: The company was acquired by Lauxera Capital Partners through an LBO on November 25, 2024 for an undisclosed amount. The company is a developer of an FDA-compliant cloud-based software system for medical device connectivity, data visualization, and analytics.

Intera Oncology / Boston Scientific: The company reached a definitive agreement to be acquired by Boston Scientific for an undisclosed amount as of November 25, 2024. The company is a developer of a medical device designed to substantially improve survival and standard of care for colorectal cancer and cholangiocarcinoma patients.

Medxl / Amsino International: The company was acquired by Amsino International, via its financial sponsor Novo Tellus Capital Partners, through an LBO on November 25, 2024 for an undisclosed amount. The company is a manufacturer of medical devices related to prefilled syringes used in intravenous drug therapy.

Microbe Investigations / AnaBio Technologies: The company was acquired by AnaBio Technologies, a subsidiary of Dohble Ventures, for an undisclosed amount on November 27, 2024. The company is an operator of a microbial testing laboratory intended to advance product developments of antimicrobial treatments.